Clinical trials: Primary Glioblastoma, open to volunteers
Grade II Glioma, Grade III Glioma
Implantable Microdevice In Primary Brain Tumors
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors.
- Conditions
- Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma
- Trial name
- NCT04135807
- Testing
- Microdevice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oliver Jonas
Glioblastoma, Brain Tumor, Primary
Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor
According to the latest national cancer statistics released by the National Cancer Center in February 2022, intracranial tumors account for about 60%-70% of the more than 3.5 million cancer patients, and the morbidity and…
- Conditions
- Glioblastoma, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT06929819
- Testing
- Intraoperative Radiation Therapy in Malignant Cerebral Tumor
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Brain (Nervous System) Cancers, Glioblastoma
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level.
- Conditions
- Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma
- Trial name
- EViDENCE-BT (NCT06804655)
- Testing
- Pharmacoscopy 1.0
- Where
- 3 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
GBM
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme
- Trial name
- NCT04115761
- Testing
- autologous dendritic cells
- Where
- 3 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Glioblastoma
Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.
The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and…
- Trial name
- ORGA-GLIO (NCT07029100)
- Testing
- Ex-vivo organoid culture
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Henri Becquerel
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Primary Malignant Brain Tumor, Glioblastoma (GBM)
FearLess in NeuroOncology
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant…
- Conditions
- Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- NCT06989086
- Testing
- Fearless in Neuro-Oncology
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Virginia Commonwealth University
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Central Nervous System Cancer, Brain Metastases
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months…
- Trial name
- NCT07462507
- Testing
- [C-11]-CS1P1, Brain MRI
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Washington University School of Medicine
Primary Brain Tumour, Glioblastoma
OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients
People diagnosed with primary brain tumours often experience significant symptoms such as fatigue, cognitive changes, anxiety, and reduced ability to carry out everyday activities.
- Conditions
- Primary Brain Tumour, Glioblastoma, Brain Neoplasms
- Trial name
- OTSMILE (NCT07426848)
- Testing
- Standard Lifestyle Management Literature, OT SMILE Occupational Therapy Group Programme
- Where
- Ireland
- Volunteers
- 96 people
- Sponsor
- Royal College of Surgeons, Ireland
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Ependymoma, Medulloblastoma
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells.
- Conditions
- Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
- Trial name
- NCT05106296
- Testing
- Indoximod, Ibrutinib, Cyclophosphamide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Theodore S. Johnson
Primary Glioblastoma
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Glioblastomas (GBM) are the most frequent brain tumors and one of the most lethal adult cancers despite maximal multimodal therapy.
- Trial name
- MATVAC-1 (NCT07347210)
- Testing
- UCPVax, Pembrolizumab, Temozolomide
- Where
- 4 sites in France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Glioblastoma Multiforme (GBM), Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult
- Trial name
- CAPTEM (NCT03213002)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Northwell Health
Glioblastoma
Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma
This is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will…
- Trial name
- NCT07789379
- Testing
- Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy
- Volunteers
- 94 people
- Sponsor
- Wei Jiang
Glioblastoma, Glioma
Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain Lesions.
Neurovascular uncoupling (NVU) represents a major source of potential bias for the identification of eloquent brain regions through activation procedures in blood oxygen level dependent (BOLD) functional magnetic resonance…
- Conditions
- Glioblastoma, Glioma, Astrocytoma
- Trial name
- NVUCVR (NCT06797661)
- Testing
- Functional MRI, FDG-PET, Structural MRI
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Erasme University Hospital